Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 401–500 of 1,000
Structure-based Ligand Design and the Promise Held for Antiprotozoan Drug Discovery
Hunter, W. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800072200 · Cited by 46
Target Essentiality and Centrality Characterize Drug Side Effects
Wang, X., Thijssen, B., & Yu, H. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003119 · Cited by 46
“Previous studies have shown that drugs with shared targets or those that are close in the interactome network often share similar side effects [13,14].”
BackgroundStructural and Functional View of Polypharmacology
Moya‐García, A. A., Adeyelu, T. T., Krüger, F. A., Dawson, N. L., Lees, J., Overington, J. P., Orengo, C. A., & Ranea, J. A. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-10012-x · Cited by 47
A Novel Approach for Drug-Target Interactions Prediction Based on Multimodal Deep Autoencoder
Wang, H., Wang, J., Dong, C., Lian, Y., Liu, D., & Yan, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01592 · Cited by 43
From protein interaction networks to novel therapeutic strategies
Jaeger, S., & Aloy, P. (2012) · IUBMB Life · doi:10.1002/iub.1040 · Cited by 43
“considered phenotypic side-effect similarities to identify common protein targets of unrelated drugs as novel therapeutic targets (73).”
BackgroundPositive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes
Hameed, P. N., Verspoor, K. M., Kusljic, S., & Halgamuge, S. K. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1546-7 · Cited by 48
“Drug interactions like physiological properties cannot be predicted by chemical properties alone, since drugs undergo complicated metabolic transformations and other pharmacokinetic transformations as they are metabolized and physiologically distributed [26, 27].”
BackgroundWang, Q., Feng, Y., Huang, J., Wang, T., & Cheng, G. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176486 · Cited by 42
Network-based cancer precision medicine: A new emerging paradigm
Tan, A., Huang, H., Zhang, P., & Li, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.015 · Cited by 46
Jung, Y.-S., Kim, Y., & Cho, Y. (2021) · Methods · doi:10.1016/j.ymeth.2021.10.007 · Cited by 44
Molecular Mimicry-Based Repositioning of Nutlin-3 to Anti-Apoptotic Bcl-2 Family Proteins
Ha, J., Won, E.-Y., Shin, J., Jang, M. K., Ryu, K., Bae, K., Park, S. G., Park, B. C., Yoon, H. S., & Chi, S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja109521f · Cited by 43
Network approaches to drug discovery
Chandra, N. R., & Padiadpu, J. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741119 · Cited by 46
“For example, drug sub-networks around the antiulcer drug rabeprazole were predicted by drug-target relations which were later experimentally validated [23] .”
BackgroundDeepACTION: A deep learning-based method for predicting novel drug-target interactions
Mahmud, S., Chen, W., Jahan, H., Dai, B., Din, S. U., & Dzisoo, A. M. (2020) · Analytical Biochemistry · doi:10.1016/j.ab.2020.113978 · Cited by 42
Network analysis has diverse roles in drug discovery
Hasan, S., Bonde, B. K., Buchan, N. S., & Hall, M. D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.006 · Cited by 43
González‐Díaz, H., Prado-Prado, F., Sobarzo‐Sánchez, E., Haddad, M., Chevalley, S., Valentin, A., Quetin‐Leclercq, J., Dea‐Ayuela, M. A., Gómez-Muñoz, M. T., Munteanu, C. R., et al. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.01.010 · Cited by 44
“There are different similarity values for drugs and proteins in the literature (Campillos et al., 2008; Geppert et al., 2009; Good et al., 1992; Lam and Welch, 2004; Thimm et al., 2004; Wang and Bajorath, 2009; Xie et al., 2009).”
BackgroundHu, Y., & Bajorath, J. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9488-0 · Cited by 45
Dimova, D., Hu, Y., & Bajorath, J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301292a · Cited by 45
Laufkötter, O., Sturm, N., Bajorath, J., Chen, H., & Engkvist, O. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0376-1 · Cited by 41
Jacoby, E. (2011) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.11 · Cited by 46
“Related are drug target identification studies using the concept of side-effect similarity introduced by Campillos et al. 45 On the basis of side-effect profiles of drugs abstracted using the unified medical language system ontology for medical symptoms and drug package inserts predictive correlation…”
MethodOptimal drug combinations and minimal hitting sets
Vázquez, A. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-81 · Cited by 46
Dai, Q., & Gao, Y. (2023) · Artificial intelligence: foundations, theory, and algorithms/Artificial intelligence: Foundations, theory, and algorithms · doi:10.1007/978-981-99-0185-2 · Cited by 44
Drug–disease association prediction with literature based multi-feature fusion
Kang, H., Hou, L., Gu, Y., Lu, X. T., Li, J., & Li, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205144 · Cited by 42
Computational Drug Repositioning by Ranking and Integrating Multiple Data Sources
Zhang, P., Agarwal, P., & Obradovic, Z. (2013) · Lecture notes in computer science · doi:10.1007/978-3-642-40994-3_37 · Cited by 47
“We consider multiple chemical properties, biological properties, and phenotypic properties at the same time, unlike references [4-11].”
BackgroundMethodWang, Y., Li, C., Liu, Z., Shi, T., Wang, Q., Li, D., Wu, Y. L., Han, J., Guo, S., Tang, B., et al. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-67 · Cited by 40
“In recent years, researchers have developed some bioinformatic methods to infer drug–target interactions [10-15], which provide opportunities to conduct more efficient research on the efficacy of the entire formula.”
BackgroundVilar, S., & Hripcsak, G. M. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw048 · Cited by 51
Knowledge Discovery from Biomedical Ontologies in Cross Domains
Shen, F., & Lee, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160005 · Cited by 39
Molecular similarity-based predictions of the Tox21 screening outcome
Drwal, M. N., Siramshetty, V. B., Banerjee, P., Goede, A., Preißner, R., & Dunkel, M. (2015) · Frontiers in Environmental Science · doi:10.3389/fenvs.2015.00054 · Cited by 39
“Similaritybased methods have been successfully applied to solve various research questions including predictions of targets (Campillos et al., 2008), therapeutic indications (Nickel et al., 2014) or side-effects (Lounkine et al., 2012).”
Cao, D., Xiao, N., Li, Y., Zeng, W., Liang, Y., Lu, A., Xu, Q., & Af, C. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12002 · Cited by 43
“18,19 Currently, a large-scale study proposed by Kuhn et al . systematically identifies protein-ADR associations by correlating drug–target interaction data with drug–ADR interaction data.”
BackgroundGarcía‐Sosa, A. T., Oja, M., Hetényi, C., & Maran, U. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200587h · Cited by 40
Mining Significant Substructure Pairs for Interpreting Polypharmacology in Drug-Target Network
Takigawa, I., Tsuda, K., & Mamitsuka, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016999 · Cited by 40
“3) Many approved drugs, potentially the majority of therapeutic agents, are less selective than initially thought [3].”
BackgroundInfluentialNovel opportunities for computational biology and sociology in drug discovery
Yao, L., Evans, J. A., & Rzhetsky, A. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.06.003 · Cited by 43
“These methods have been used in biomedicine to discover multi-molecular processes in complex databases containing biological and clinical information [10].”
BackgroundMethodNetwork-Based Drug Ranking and Repositioning with Respect to DrugBank Therapeutic Categories
Ré, M., & Valentini, G. (2013) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2013.62 · Cited by 43
“For more details about computational methods for drug repositioning based on chemical similarity [2], molecular activity similarity [6], [14], molecular docking [15], shared molecular patology [16], and side-effect similarities [17], we refer the reader to the Dudley et al.”
MethodiDrug: a web-accessible and interactive drug discovery and design platform
Wang, X., Chen, H., Yang, F., Gong, J., Li, S., Pei, J., Liu, X., Jiang, H., Lai, L., & Li, H. (2014) · Journal of Cheminformatics · doi:10.1186/1758-2946-6-28 · Cited by 42
“A huge body of CADD software has been developed over the years in many different research groups [3-11].”
BackgroundComputational drug repositioning using collaborative filtering via multi-source fusion
Zhang, J., Li, C., Lin, Y., Shao, Y., & Li, S. (2017) · Expert Systems with Applications · doi:10.1016/j.eswa.2017.05.004 · Cited by 40
Inverse similarity and reliable negative samples for drug side-effect prediction
Zheng, Y., Peng, H., Ghosh, S., Lan, C., & Li, J. (2019) · BMC Bioinformatics · doi:10.1186/s12859-018-2563-x · Cited by 41
Srivastava, A., Siddiqui, S., Ahmad, R., Mehrotra, S., Ahmad, B., & Srivastava, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1835725 · Cited by 42
“Swiss Target Prediction (http://www.swisstargetprediction.ch.) is an online web-based interface which helps in finding bioactive molecules having similar configuration with related or similar biochemical targets (Campillos et al., 2008).”
BackgroundXu, R., & Wang, Q. (2013) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2013.10.008 · Cited by 39
“It has been increasingly recognized that similar side effects of seemingly unrelated drugs can be caused by their common off-targets and that drugs with similar side effects are likely to share molecular targets [19].”
BackgroundPrediction and Evaluation of Protein Farnesyltransferase Inhibition by Commercial Drugs
DeGraw, A. J., Keiser, M. J., Ochocki, J. D., Shoichet, B. K., & Distefano, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901613f · Cited by 46
Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery
Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.004 · Cited by 38
Cause-effect relationships in medicine: a protein network perspective
Fliri, A. F. J., Loging, W., & Volkmann, R. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.07.005 · Cited by 39
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
Laganà, A., Beno, I., Melnekoff, D. T., Leshchenko, V. V., Madduri, D., Ramdas, D., Sanchez, L. J., Niglio, S. A., Perumal, D., Kidd, B. A., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00019 · Cited by 38
“8,9 The rationale behind this approach is that a drug inducing a gene expression profile that is opposite to a patient’s profile might be able to revert the disease-associated signature and the phenotype.”
In Silico Target Prediction for Small Molecules
Byrne, R., & Schneider, G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8891-4_16 · Cited by 47
In silico drug repositioning based on drug-miRNA associations
Zhou, X., Dai, E., Song, Q., Ma, X., Meng, Q., Jiang, Y., & Jiang, W. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz012 · Cited by 39
Zhao, S., Tian, R., Shao, B., Feng, Y., Yuan, S., Dong, L., Zhang, L., Wang, Z., & You, H. (2019) · Nanoscale · doi:10.1039/c9nr09401f · Cited by 38
Karatzas, E., Zamora, J. E., Athanasiadis, E. I., Dellis, D., Cournia, Z., & Spyrou, G. M. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz976 · Cited by 39
“Generating these libraries through exploration of this space is a challenge in itself, and several researchers have tackled the problem through different computational approaches, such as exhaustive search (Gómez-Bombarelli et al., 2016), genetic algorithms (Virshup et al., 2013) and recently, deep neural networks (Gó…”
BackgroundDrug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Roy, S., Dhaneshwar, S. S., & Bhasin, B. (2021) · Current Drug Research Reviews · doi:10.2174/2589977513666210211163711 · Cited by 42
The chemist as astronaut: Searching for biologically useful space in the chemical universe
Triggle, D. J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.015 · Cited by 39
“Partial validation of this approach was derived by examining the phenotypic sideeffect similarities of some 746 marketed drugs to derive a network of drug–drug relations, a significant fraction of which were generated by distinct molecular entities from different therapeutic indications [53,54].”
MethodExploring drug combinations in genetic interaction network
Wang, Y., Xu, K., Song, J., & Zhao, X. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s7-s7 · Cited by 39
“In particular, the non-specific target proteins were discarded as described in [24].”
BackgroundDrug Target Group Prediction with Multiple Drug Networks
Che, J., Chen, L., Guo, Z., Wang, S., & Aorigele (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/18755402otkzfmzcstcvy · Cited by 39
Network-Based Methods and Their Applications in Drug Discovery
Yu, Z., Wu, Z., Wang, Z., Wang, Y., Zhou, M., Li, W., Liu, G., & Tang, Y. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01613 · Cited by 38
Automatic Filtering and Substantiation of Drug Safety Signals
Bauer‐Mehren, A., van Mulligen, E. M., Avillach, P., Carrascosa, M. D. C., García-Serna, R., Piñero, J., Singh, B., Lopes, P. H. D. M. B., Oliveira, J. L., Diallo, G., et al. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002457 · Cited by 40
“Analysis of drug-event pairs from SIDER In addition to the example case presented above, the ADR-S workflow was evaluated on a large-scale data set.”
BackgroundMethodInfluentialBuilding a drug–target network and its applications
Lee, S., Park, K., & Kim, D. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903322234 · Cited by 39
“Along with the construction of a drug–target network, other types of networks, such as drug–disease networks, drug–side effect networks and drug–molecular fragment networks, have been developed by various researchers [6,7] .”
BackgroundHizukuri, Y., Sawada, R., & Yamanishi, Y. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0158-1 · Cited by 37
“Recently, the use of information on the side effects of drugs has been proposed as an alternative method for target predictions [8 – 10].”
MethodWang, Y., Fang, J., & Chen, S. (2016) · Scientific Reports · doi:10.1038/srep32679 · Cited by 45
Schuler, J., Hudson, M. L., Schwartz, D. G., & Samudrala, R. (2017) · Molecules · doi:10.3390/molecules22101777 · Cited by 39
Predicting Drug-Target Interactions Using Drug-Drug Interactions
Kim, S., Jin, D., & Lee, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080129 · Cited by 39
“In a previous study, the chemical structure and side effect similarities of drugs were shown to be useful for predicting the drug’s target proteins [17]; i.”
BackgroundMethodInfluentialHutz, J., Nelson, T., Wu, H. J., McAllister, G., Moutsatsos, I. K., Jaeger, S. A., Bandyopadhyay, S., Nigsch, F., Cornett, B., Jenkins, J. L., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112469257 · Cited by 42
Li, H., Zou, L., Kowah, J. A. H., He, D., Wang, L., Yuan, M., & Liu, X. (2023) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-023-00558-y · Cited by 40
“The first source was derived from calculations in a publication [41], which suggested that drugs sharing a single target may have synergistic effects, and the probability of a large number of drugs sharing a single target was calculated and experimentally validated.”
BackgroundCharacterizing the Network of Drugs and Their Affected Metabolic Subpathways
Li, C., Shang, D., Wang, Y., Li, J., Han, J., Wang, S., Yao, Q., Wang, Y., Zhang, Y., Zhang, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047326 · Cited by 36
“To date, many studies on drugs and their affected subpathways have been limited to low-throughput experiments and many large scale studies on drugs have only focused on one aspect of drug impact (therapeutic effects or side effects) [5,21,24,25].”
BackgroundKinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data
Yang, X., Huang, Y., Crowson, M., Li, J., Maitland, M. L., & Lussier, Y. A. (2010) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2010.04.006 · Cited by 36
“A relevant recent study uncovered 12 drug-target relationships by means of predicting relationships using phenotypic adverse event similarities; they further validated all of these relationships and successfully confirmed 9 of the relationships using in vitro binding assays[16].”
Liu, M., Cai, R., Hu, Y. Q., Matheny, M. E., Sun, J., Hu, J. X., & Xu, H. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2013-002051 · Cited by 38
Use of big data in drug development for precision medicine
Kim, R. S., Goossens, N., & Hoshida, Y. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1174062 · Cited by 41
“Another unique approach is to use similarity in side-effect profiles [58].”
Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials
Federer, C., Yoo, M., & Tan, A. C. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.742 · Cited by 43
Han, Z., Xue, W., Tao, L., & Zhu, F. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13051 · Cited by 37
Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy
El-Hachem, N., Gendoo, D. M. A., Ghoraie, L. S., Safikhani, Z., Smirnov, P., Chung, C., Deng, K., Fang, A., Birkwood, E., Ho, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0096 · Cited by 41
“Other methods have integrated prior knowledge such as adverse effects annotations (10,11) and recent approaches showed that integrating multiple layers of information had improved Anatomical Therapeutic Classification system (ATC) prediction for FDA-approved drugs (12).”
MethodUniconazole, a cytochrome P450 inhibitor, inhibits trans-zeatin biosynthesis in Arabidopsis
Sasaki, E., Ogura, T., Takei, K., Kojima, M., Kitahata, N., Sakakibara, H., Asami, T., & Shimada, Y. (2012) · Phytochemistry · doi:10.1016/j.phytochem.2012.11.023 · Cited by 36
“Although unexpected activities derived from off-targets are usually undesired and harmful, studies of off-targets provide us with valuable information to discover new targets of the inhibitors (Campillos et al., 2008).”
BackgroundChen, L., Li, B., Zheng, M.-Y., Zhang, J., Feng, K., & Cai, Y. (2013) · BioMed Research International · doi:10.1155/2013/723780 · Cited by 38
“In general, drugs are combined according to the mechanisms of action, which is characterized by the properties of drugs including their pharmacology and targets [10, 11].”
BackgroundExploiting Online Discussions to Discover Unrecognized Drug Side Effects
Fang, H., Stanhope, S. J., & Wu, H. (2013) · Methods of Information in Medicine · doi:10.3414/me12-02-0004 · Cited by 41
“The interaction between a drug and its intended targets can treat the diseases associated with the targets, while the interaction with “offtargets” may make drugs less effective or even cause dangerous side effects such as heart failure [1–3].”
BackgroundHuang, C., Chang, P. M., Hsu, C.-W., Huang, C. F., & Ng, K. (2016) · BMC Bioinformatics · doi:10.1186/s12859-015-0845-0 · Cited by 38
“…repositioned drugs have been based on various computational methods, such as mapping gene expression profiles using drug response profiles [10 – 14], the use of side-effect-based similarities [15 – 17], heterogeneous network clustering [18], and the graph-based inference method [19 – 22].”
MethodOne Drug for Multiple Targets: A Computational Perspective
Méndez‐Lucio, O., Naveja, J. J., Vite‐Caritino, H., Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2017) · Journal of the Mexican Chemical Society · doi:10.29356/jmcs.v60i3.100 · Cited by 36
Rational Application of Drug Promiscuity in Medicinal Chemistry
Mei, Y., & Yang, B. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0018 · Cited by 37
Chae, H., Kwak, D., Lee, M., Chi, S., & Kim, K. B. (2018) · Nanoscale · doi:10.1039/c8nr06423g · Cited by 35
Measure clinical drug–drug similarity using Electronic Medical Records
Zeng, X. L., Jia, Z., He, Z., Chen, W., Lü, X., Duan, H., & Li, H. (2019) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.02.003 · Cited by 36
Zhou, M., Zheng, C., & Xu, R. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa451 · Cited by 34
Learning Universal Network Representation via Link Prediction by Graph Convolutional Neural Network
Gu, W., Gao, F., Li, R., & Zhang, J. (2021) · Journal of Social Computing · doi:10.23919/jsc.2021.0001 · Cited by 35
Ruan, D., Ji, S., Yan, C. C., Zhu, J., Zhao, X., Yang, Y., Gao, Y., Zou, C., & Dai, Q. (2021) · Patterns · doi:10.1016/j.patter.2021.100390 · Cited by 43
“Campillos et al. 18 constructed a network of 1,018 side effect-driven drug-drug relations and validated 13 implied drug-target relations.”
BackgroundLiu, T., & Altman, R. B. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00030 · Cited by 35
Genome-Scale Screening of Drug-Target Associations Relevant to Ki Using a Chemogenomics Approach
Cao, D., Liang, Y., Deng, Z., Hu, Q., He, M., Xu, Q., Zhou, G., Zhang, L., Deng, Z., & Liu, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057680 · Cited by 39
“The final is from the research work of Keiser and Campillos [13,67].”
BackgroundMethodWagner, B. K., & Clemons, P. A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.09.018 · Cited by 38
Drug Target Prediction by Multi-View Low Rank Embedding
Li, L., & Cai, M. (2017) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2017.2706267 · Cited by 35
“[4] make use of drug side effects to measure the similarity among drugs, which pave a new way to represent drugs.”
BackgroundNovel opportunities for computational biology and sociology in drug discovery
Yao, L., Evans, J. A., & Rzhetsky, A. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.01.004 · Cited by 41
The opportunities of mining historical and collective data in drug discovery
Wassermann, A. M., Lounkine, E., Davies, J. W., Glick, M., & Camargo, L. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.004 · Cited by 34
Drug name recognition in biomedical texts: a machine-learning-based method
He, L., Yang, Z., Lin, H., & Li, Y. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.006 · Cited by 35
Exploring the relationship between drug side-effects and therapeutic indications.
Zhang, P., Wang, F., Hu, J., & Sorrentino, R. (2013) · Europe PMC (PubMed Central) · Cited by 49
Adachi, J., Kishida, M., Watanabe, S., Hashimoto, Y., Fukamizu, K., & Tomonaga, T. (2014) · Journal of Proteome Research · doi:10.1021/pr500845u · Cited by 37
Discovering the Targets of Drugs Via Computational Systems Biology
Chua, H. N., & Roth, F. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.174797 · Cited by 37
Drug Effects Viewed from a Signal Transduction Network Perspective
Fliri, A. F. J., Loging, W., & Volkmann, R. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901001p · Cited by 37
Computational drug repositioning based on side-effects mined from social media
Nugent, T., Plachouras, V., & Leidner, J. L. (2016) · PeerJ Computer Science · doi:10.7717/peerj-cs.46 · Cited by 40
“If we assume that a higher ranking in our model indicates a higher likelihood of drugs sharing a protein target, this relationship demonstrates similar properties to the observations of Campillos et al. [20] in that there is a negative correlation between the rank and frequency of a side-effect.”
ResultChen, H., & Li, J. (2019) · International World Wide Web Conference (WWW) · doi:10.1145/3308558.3313476 · Cited by 40
“Auxiliary information: Following several previous studies [7, 9, 20, 30, 45], we collect auxiliary information from different datasets with respect to drugs, targets, and diseases.”
BackgroundMethodXu, R., & Wang, Q. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.06.027 · Cited by 34
“Drug-based approaches leverage on the known molecular structures or functions of drugs, such as chemical structures and properties, molecular docking, gene expression, drug treatment indications, and drug side effects [16, 17, 18, 19, 20, 21, 22, 23, 24].”
BackgroundA chemogenomics view on protein-ligand spaces
Strömbergsson, H., & Kleywegt, G. J. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s6-s13 · Cited by 33
“[20] explored known side-effects information of marketed drugs to induce a drug-drug target relation network, which resulted in the prediction and successful experimental validation of a number of novel drug-drug target interactions.”
BackgroundXue, R., Liao, J., Shao, X., Han, K., Long, J., Shao, L., Ai, N., & Fan, X. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00238 · Cited by 33
Deciphering the molecular basis of human cardiovascular disease through network biology
Chan, S. Y., White, K., & Loscalzo, J. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283515b31 · Cited by 36
“Notably, a recent analysis revealed that a large proportion of established drugs do not target actual disease-associated proteins but merely proteins in their network neighborhood [26].”
BackgroundThe relationship between rational drug design and drug side effects
Wang, J., Li, Z., Qiu, C., Wang, D., & Cui, Q. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr061 · Cited by 34
“The similarity of side effects between two drugs could be an important metric to identify novel drug targets [6].”
BackgroundPharmacovigilance as Scientific Discovery: An Argument for Trans-Disciplinarity
Rocca, E., Copeland, S. M., & Edwards, I. R. (2019) · Drug Safety · doi:10.1007/s40264-019-00826-1 · Cited by 39
Systems Biology Approaches to a Rational Drug Discovery Paradigm
Prathipati, P., & Mizuguchi, K. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150826114524 · Cited by 35
Zhang, C., Hong, H., Mendrick, D. L., Tang, Y., & Cheng, F. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.81 · Cited by 34
DTome: a web-based tool for drug-target interactome construction
Sun, J., Wu, Y., Xu, H., & Zhao, Z. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s9-s7 · Cited by 34
“Network-based approaches have been successfully applied to numerous areas in pharmacology, including novel target prediction for known drugs [10-12], identification of drug repositioning and combination [13-15], and inference of potential drug-disease associations [16].”
BackgroundThe integrated disease network
Sun, K., Buchan, N. S., Larminie, C., & Pržulj, N. (2014) · Integrative Biology · doi:10.1039/c4ib00122b · Cited by 34
Carrieri, A., Pérez‐Nueno, V. I., Lentini, G., & Ritchie, D. W. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990028 · Cited by 32
“These range from the well-known docking of compounds into protein structures to the use of network pharmacology and machine learning methods [139-141], sequence comparison [142], side-effect similarity [131,143] or chemogenomic approaches such as fingerprint/pharmacophore comparison methods [144].”
BackgroundA Recommender System Approach for Predicting Drug Side Effects
Galeano, D., & Paccanaro, A. (2018) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn.2018.8489025 · Cited by 36
“The first is important to understand the soff-target proteins that cause the side effect [19], whereas the latter because most treatments consist of drug combinations that can lead to unseen and unpredictable”
Background
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.